Grifols, S.A. (NASDAQ: GRFS) shares are trading higher after the company reached a strategic Alliance and share purchase agreement with Haier Group Corp to sell approximately a 20% equity stake in Shanghai RAAS (SRAAS) in exchange for roughly $1.8 billion.
The two companies will explore opportunities to combine Grifols' plasma and diagnostic excellence with Haier's portfolio of healthcare solutions.
Grifols and Haier envision broad cooperation to contribute to China's growing and developing healthcare system.
"China remains core to our growth strategy. We are ...